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• Antiphospholipid antibodies (aPL) are heterogeneous and induce different cellular responses.
• We analyzed signaling events induced by different monoclonal and patient aPL in monocytes.
• Two major signaling pathways involving either NADPH-oxidase or LRP8 were identified.
• Our data suggest that these two pathways mediate the majority of aPL effects on monocytes.
Summary. Background: Antiphospholipid antibodies (aPLs) contribute to the pathogenesis of the antiphospholipid syndrome (APS) by induction of an inflammatory and procoagulant state in different cell types, and several signaling pathways have been described. Objectives: To investigate whether signaling depends on the epitope specificity of aPLs. Methods: Cellular effects of three human monoclonal aPLs with distinctly different epitope specificities were analyzed in vitro. Expression of tumor necrosis factor-a mRNA by mouse and human monocytes was the major readout. Analysis included cells from genetically modified mice, and the use of specific inhibitors in human monocytes. Data were validated with IgG isolated from 20 APS patients. Results: Cofactor-independent anticardiolipin aPLs activated monocytes by induction of endosomal NADPH oxidase. Activation could be blocked by hydroxychloroquine (HCQ). Anti-b 2 -glycoprotein I aPL activated monocytes by interacting with LDL receptor-related protein 8 (LRP8). This could be blocked by rapamycin. Analysis of 20 APS patients' IgG showed that all IgG fractions activated the same two pathways as the monoclonal aPL, depending on their epitope patterns as determined by ELISA. Monocyte activation by APS IgG could be blocked completely by HCQ and/or rapamycin, suggesting that in most, if not all,
Introduction
The antiphospholipid syndrome (APS) is a severe autoimmune disease characterized by venous and/or arterial thrombosis or pregnancy morbidity in women combined with the persistent presence of antiphospholipid antibodies (aPLs). Although there is a general consensus that aPLs detected in APS patients causes the clinical manifestations of APS, the underlying mechanisms are still being debated [1] [2] [3] [4] [5] . The large interindividual but also intraindividual heterogeneity of aPLs poses a major challenge for researchers trying to elucidate specific pathogenic mechanisms. aPLs that bind to anionic phospholipids, e.g. cardiolipin alone or in combination with phospholipidbinding proteins, so-called cofactors, of which b 2 -glycoprotein I (b 2 GPI) is the most important, have been described. Furthermore, there are antibodies that bind exclusively to the cofactors, mainly to b 2 GPI, which are usually subsumed under the heading aPLs. Finally, there are some aPLs that inhibit phospholipid-dependent clotting assays, e.g. the activated partial thromboplastin time. These antibodies are collectively called lupus anticoagulants (LAs), because they were initially recognized in patients with systemic lupus erythematosus (SLE).
Currently, the induction of cellular inflammatory and procoagulant responses is considered to be a major pathogenic action of aPLs. Several such cellular responses can be elicited by aPLs, and important insights into the underlying signaling processes have been obtained in recent years [6, 7] . These data suggest that different aPL subtypes may induce specific signaling cascades. However, a systematic attempt to determine which aPL specificity is responsible for which signaling event has not been undertaken. This is because most studies were performed with whole sera or IgG fractions obtained from APS patients. These IgG fractions are inherently heterogeneous, so that cellular responses cannot be attributed to a specific aPL subtype. Attempts to separate aPL subtypes by affinity procedures have so far been unsuccessful [5] . The use of monoclonal aPLs derived from APS patients is an alternative to work around this problem. However, the relevance of effects observed with monoclonal aPLs for APS pathophysiology has to be proven. The most appropriate way to do this is to reproduce the effects of monoclonal aPLs with IgG fractions from several APS patients.
In the present study, we used three different human monoclonal aPLs isolated from APS patients [8] [9] [10] . We compared their effects on monocytes and the underlying signaling mechanisms in vitro. In a second step, we analyzed the ability of IgG fractions from APS patients to activate the signaling pathways activated by the monoclonal aPLs, and correlated this with their binding reactivity in aPL assays.
Materials and methods

Antibodies and reagents
The human monoclonal aPLs HL5B and HL7G have been described in detail previously [8, 10] . JGG9 is an anti-b 2 GPI aPL of the IgM isotype [9] that was converted to an IgG isotype by the use of recombinant DNA technology (rJGG9). IgGs of 20 APS patients and 20 healthy control donors were purified from serum by protein G affinity chromatography with HiTrap protein G HP columns (GE Healthcare Bio-Sciences, M€ unchen, Germany) via FPLC or HPLC with reduced flow rates. IgG purity in eluted fractions was confirmed by gradient gel electrophoresis (Ready Gels 4-15% Tris-HCl 10 wells; BioRad, Munich, Germany). Fractions containing pure antibody were pooled and buffered in phosphate-buffered saline (PBS). The concentration of IgG was determined with a home-made assay [11] . All antibody preparations were tested for the presence of LPS with the Limulus amoebocyte assay, and had undetectable LPS concentrations (< 0.1 U mL À1 [13] were obtained from Jackson Laboratories (Bar Harbor, ME, USA). LRP8-deficient mice had been backcrossed to the C57BL/6J mouse strain for at least nine generations. CD115 + cells were isolated from the spleens of 6-10-week-old mice with paramagnetic CD115 beads on LS columns (Miltenyi Biotec, Bergisch Gladbach, Germany), according to the manufacturer's instructions. All animal procedures were performed in accordance with German regulations, and were approved by the local authority (Landesuntersuchungsamt Rheinland-Pfalz, Koblenz, Germany).
Cell culture and stimulation of cells
CD115
+ splenocytes or MonoMac1 (MM1) cells were maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum, L-glutamine, and sodium pyruvate. Human monocytes were isolated from buffy coats provided by the Transfusion Center of the University Medical Center Mainz, as previously described [11] . Monoclonal HL5B, HL7G (500 ng mL À1 each), rJGG9, IgG control (1 lg mL À1 each) or purified IgG (100 lg mL À1 ) fractions were added as indicated to 0.5 9 10 6 cells mL À1 .
The inhibitors rapamycin (5 nM; rapa) and HCQ (1 lM)
were added to the cells 15 min before the stimuli. To analyze gene expression, RNA was isolated, and quantitative reverse transcription PCR was performed as previously described [14] .
Statistics
All data shown are means AE standard deviation. The results were analyzed with one-way ANOVA followed by the Student-Newman-Keuls test where appropriate. P < 0.05 was considered to be statistically significant.
Results
Binding specificity of monoclonal aPLs
Three monoclonal aPLs isolated from APS patients were used: HL5B, HL7G, and rJGG9. The binding specificities of the monoclonal aPLs were verified with immunoassays, as described above. In the absence of any protein cofactor, only HL5B and, to a lesser degree, HL7G bound to cardiolipin-coated wells. Addition of human serum (10%) or b 2 GPI (10 lg mL À1 ) had no effect on binding of HL5B, but significantly increased binding of HL7G and rJGG9 ( Fig. S1 ). On the other hand, HL5B did not bind to b 2 GPI-coated wells, whereas HL7G and rJGG9 showed strong binding (Fig. S2 ). It should be noted that rJGG9 reacts in commercial anticardiolipin assays that are supplemented with b 2 GPI. Thus, the distinction described here can only be made if the cardiolipin assay does not contain b 2 GPI or any other protein cofactor. To further characterize the epitope specificity of HL7G and rJGG9 on b 2 GPI, they were tested for their ability to bind to domain-1 of b 2 GPI. Only rJGG9 showed a strong reaction against domain-1, and HL7G did not react in this assay. The binding spectrum of the three monoclonal aPLs is summarized in Table 1 .
Effects of monoclonal aPLs on mouse monocytes
We compared the ability of the three monoclonal aPLs to induce proinflammatory pathways in cultured mouse (C57BL/6J) monocytes. The primary readout that we used was induction of tumor necrosis factor (TNF)-a gene expression, because preliminary experiments had shown that this cytokine is induced by all three aPLs (Table S1 ). Tissue factor (TF) has also been reported to be induced by aPLs; however, we observed that TF induction by rJGG9 in mouse monocytes was secondary to TNF-a secretion. Coincubation with the TNF-a antibody adalimumab completely prevented TF induction (Fig. S3 ). All three monoclonal aPLs greatly induced TNF-a mRNA, but with distinct time courses (Fig. 1A-C ). TNF-a induction by HL5B peaked at 6 h and declined rapidly thereafter. TNFa induction by HL7G also reached a maximum at 6 h, but was sustained for another 6-9 h before declining. TNF-a induction by rJGG9 was less pronounced and much slower, with a maximum at approximately 12-15 h. To further characterize the underlying signaling mechanisms, we used monocytes isolated from mice deficient in key molecules implicated in aPL signaling, i.e. TLR2, TLR4, LRP8, and gp91phox, the catalytic subunit of NADPH oxidase (NOX) 2. All mouse strains were on the C57BL/6J background. Cells from gp91phox À/À mice did not respond to HL5B, but showed an almost unchanged response to rJGG9 (Fig. 1A,C) . On the other hand, monocytes from LRP8 À/À mice did not respond to rJGG9, but showed the same response to HL5B as wildtype cells (Fig. 1D,F) . This confirms our previous data that HL5B signaling is fully dependent on NOX2 [15, 16] . In addition, it shows that rJGG9 depends on LRP8, consistent with previous data on anti-b 2 GPI [17, 18] . The response to HL7G was diminished in both types of knockout cells, but it was never completely lost (Fig. 1B,  E ). This indicates that HL7G can activate both pathways, which is consistent with its binding activity in ELISAs. As TLR2 and TLR4 have been implicated in signaling of aPLs [6, 7] , we analyzed monocytes from TLR2 À/À and TLR4 À/À mice ( Fig. 1G-I ). Consistent with our previous data, the effects of HL5B were not affected in these cells [19] . TNF-a induction by rJGG9 was reduced by 42% AE 15% in TLR2 À/À monocytes and by 79% AE 6% in TLR4 À/À monocytes after 15 h. The residual effect of rJGG9 in these two cell types suggests that both TLRs enhance rJGG9 signaling but are not absolutely required for this. HL7G-induced TNF-a transcription was only affected in the late phase (i.e. from the 6-h time point) by TLR2 or TLR4, consistent with an effect on anti-b 2 GPIassociated signaling.
We have shown previously that the cellular effects of HL5B can be blocked by HCQ [20] . Mammalian target of rapamycin (mTOR) has been implicated in signal transduction by anti-b 2 GPI [21, 22] . In order to confirm that mTOR signaling is induced by monoclonal anti-b 2 GPI, we analyzed phosphorylation of S6 ribosomal protein (S6RP), which is phosphorylated by a specific kinase (S6-kinase) after activation of mTOR1 [23] . Incubation of cells with monoclonal aPLs showed that the two aPLs that bind to b 2 GPI, i.e. HL7G and rJGG9, induced phosphorylation of S6RP, whereas HL5B had no effect. Phosphorylation of S6RP could be prevented by the mTOR inhibitor rapamycin (Fig. S3A) . Next, we determined the effect of rapamycin on induction of TNF-a by rJGG9. In mouse monocytes and MM1 cells, rapamycin completely prevented induction of TNF-a by rJGG9 (Fig. 2) .
Effects of patient IgG on monocytes
Having shown that there are at least two different signaling pathways induced by different types of aPL, we hypothesized that it should be possible to identify patients who had predominantly one or the other type of aPL.
We have isolated and characterized IgG fractions from 20 patients who match the classification criteria of APS [24] and are seen regularly in our medical center. The aPLbinding characteristics of their purified IgG fractions are shown in Table 2 . There are patient IgGs that bind only to cardiolipin in a cofactor-independent manner, similarly to HL5B (group 1; n = 11), patient IgGs that bind to both antigens, similarly to HL7G (group 2; n = 7), and patient IgGs that bind only to b 2 GPI, similarly to rJGG9 (group 3; n = 2). It should be noted that we have some bias towards secondary APS on the background of SLE (14/20) . This is because most patients were from our binding of b 2 GPI, again indicating activation of mTOR (Fig. S3B) .
We next extended this analysis to the whole cohort, but focused on only one time point (6 h). Figure 4 summarizes these results. Induction of TNF-a by group 1 IgGs was, with one exception, fully dependent on NOX2. Both group 3 IgGs were fully dependent on LRP8. Group 2 IgGs apparently activated both signaling pathways, because there was only partial reduction of TNF-a induction by NOX2 deficiency or LRP8 deficiency.
Pharmacologic inhibition of aPL effects
As HCQ prevents NOX2 activation by HL5B [20] , and rapamycin prevents the cellular effects of rJGG9, we investigated the effects of these two substances on TNFa induction by patient IgG (Fig. 5) . For reasons of practicability, these experiments were performed in the monocytic cell line MM1. We have used this cell line repeatedly in the past. Also, the responses to the monoclonal aPL are practically identical to those of primary human monocytes (Fig. S4) . As expected, HCQ completely blocked TNF-a induction by group 1 IgGs, whereas rapamycin had no effect. On the other hand, rapamycin completely blocked TNF-a induction by group 3 IgGs, whereas HCQ had no effect. With group 2 IgGs, both substances alone reduced TNF-a induction. The combination of both substances completely prevented TNF-a induction, suggesting that the two pathways targeted by HCQ (endosomal NOX) and rapamycin (mTOR) account for most, if not all, signal transduction induced by aPLs. Table 2 and LDL receptor-related protein 8 (LRP8) À/À mice were stimulated for 6 h with IgG fractions (100 lg mL À1 ) of the APS patients described in Table 2 . Group 1 represents IgG fractions that bind only to cardiolipin (HL5B pattern), whereas group 3 represents IgG fractions that bind only to b 2 -glycoprotein I (b 2 GPI) (rJGG9 pattern). Group 2 IgG fractions can detect both antigens (HL7G pattern). Relative tumor necrosis factor (TNF)-a mRNA expression normalized to stimulation with a pool of control IgG fractions (n = 20) and b-actin expression was determined by quantitative reverse transcription PCR. *P = 0.0001; **P = 0.048.
Discussion
Our data provide important new insights into the pathogenesis of APS. We show that the two major aPL subtypes directed against cardiolipin and against b 2 GPI can be clearly distinguished by the cellular signaling events that they induce, even though the cellular responses show significant overlap. Thus, HL5B rapidly activates endosomal NOX2, and rJGG9 signals via LRP8, leading to activation of mTOR. Activation of NOX2 by cofactorindependent aPLs has been described by us previously [14] [15] [16] 19] . Signaling via LRP8 by anti-b 2 GPI [17, 18] and activation of mTOR [21, 22] have also been described in the past, even though a direct link between LRP8 and mTOR has not been reported so far. It is of interest that appreciable induction of TNF-a expression by anti-b 2 GPI takes several hours, which indicates that there must be intermediate, as yet unidentified, signaling steps. However, this observation is in line with previous work on this topic showing that gene induction by anti-b 2 GPI in monocytes is not immediate [25] . Our data confirm a role of TLR2 and TLR4 in signal transduction of anti-b 2 GPI [6, 7] . However, signal intensity was only reduced, and not abolished, by these two TLRs. Further analysis of their exact involvement is clearly needed. Our monoclonal aPLs show some features that have significant implications for the pathogenesis of APS. Whereas HL5B and rJGG9 induce distinct signaling pathways that correlate with their binding specificity, HL7G can activate both pathways, and shows binding properties of both HL5B and rJGG9. This proves that there are aPLs that combine different pathogenic properties in one molecule. It should be noted that HL7G was isolated from the same patient as HL5B, and that the two aPLs are extremely homologous [10] . In fact, HL7G has only a few more somatic mutations in the complementaritydetermining regions of its light and heavy chains than HL5B. This indicates that HL7G evolved directly from HL5B, or that both aPLs evolved from the same precursor during antigen-driven maturation. This proves that anti-b 2 GPI can evolve from cofactor-independent anticardiolipin antibodies.
Another important aspect exemplified by HL7G is the fact that aPLs may bind to cardiolipin in a cofactor-independent way and at the same time bind to b 2 GPI. As both binding properties of aPLs are combined in one single antibody, it is technically impossible to separate them by affinity chromatography. This may explain the notoriously unsuccessful attempts to isolate pure anti-b 2 GPI by affinity chromatography [26, 27] .
Another result that we would like to emphasize is the fact that HL7G and rJGG9 appear to have the same effects on monocytes, even though only rJGG9 binds to domain-1 of b 2 GPI. It should be noted here that the specific epitope of domain-1 presented in our assay has not been described yet. However, in the light of recent work by de Moerloose et al. [28] , specific amino acid sequences might be less important than structural motifs in the molecule. Furthermore, we cannot exclude the possibility that there might be minor differences between domain-1 antibodies and anti-b 2 GPI binding to other domains that we may have overlooked. However, it is unlikely that domain specificity has a major effect on the induction of cellular responses.
The most important result of our study is, perhaps, the observation that it is possible to reproduce the patterns of cellular responses induced by the three monoclonal aPLs with IgG fractions from 20 APS patients. Every patient could be assigned to one of the three patterns of cellular activation. IgG fractions from 11 APS patients reproduced the cellular effects of HL5B (group 1), IgG fractions from another seven APS patients showed a mixed pattern, like HL7G (group 2), and IgG fractions from two APS patients behaved like rJGG9 (group 3). Most importantly, the activation pattern could be predicted from the binding properties observed with IgG fractions in appropriate immunoassays, whereas this was not always possible when we used results from routine testing of whole serum with commercially available assays for aPLs. This is because some anti-b 2 GPIs tend to react in the b 2 GPI-containing ELISA formats for anticardiolipin antibodies.
To our knowledge, this is the first comprehensive classification of the differences in cellular effects elicited by IgG fractions from APS patients. The fact that 11 of 20 APS patients had aPLs that bind to cardiolipin in the absence of protein cofactors but had no anti-b 2 GPI underscores the so far neglected role of cofactor-independent aPLs in the pathogenesis of APS [5] . We would like to point out that the relatively high proportion of APS patients with only anticardiolipin in our cohort is not unusual. For instance, Satta et al. described a similar prevalence of different aPL species in a cohort of 32 patients recruited at a hemostasis unit [29] . In fact, they found 97% anticardiolipin-positive and 34% anti-b 2 GPIpositive patients, as compared with 90% and 45%, respectively, in out cohort.
An intriguing question is whether the 11 patients in group 1 do indeed have APS, even though their aPLs are cofactor-independent. According to the updated classification criteria for APS, patients should have anticardiolipin antibodies measured with a standardized ELISA [24] . This applies to all 11 patients in group 1. In fact, our clinical routine assays on which the initial diagnosis is based also contain b 2 GPI, as recommended by the ISTH SSC [30] . Thus, all patients have been diagnosed according to the consensus criteria and with the recommended assay format. It should be noted, however, that addition of b 2 GPI to anticardiolipin assays does not provide specificity for cofactor-dependent aPLs, because cofactor-independent aPLs are also reactive in these assays. We have discussed this issue and its implications for the role of cofactor-independent aPLs in more detail recently [5] .
The obvious question of whether the aPL pattern predicts clinical manifestations of APS cannot be answered from our relatively small, retrospective patient cohort. There was no obvious association with any of the three patterns (Table 2 ), but our study was not designed, and was therefore clearly underpowered, to provide a definitive answer.
Importantly, it should be noted that, besides the NOX2-dependent and LRP8-dependent pathways, there were apparently no other signaling pathways activated. In group 1 patients who have only aPLs directed against cardiolipin, HCQ completely prevented induction of TNF-a. We have previously shown that this effect is mediated by inhibition of endosomal NOX2 [20] . As literature data suggested that rapamycin might inhibit signaling induced by anti-b 2 GPI, we tested this with rJGG9 and our patients (group 3). Indeed, rapamycin could block anti-b 2 GPIinduced signaling and mimic the effect of LRP8 deficiency. This suggests that at least induction of TNF-a by antib 2 GPI is fully dependent on mTOR signaling. Most importantly, the combination of HCQ and rapamycin completely prevented TNF-a induction by IgG from group 2 patients, i.e. patients with both anticardiolipin and anti-b 2 GPI. We interpret these data as being in strong support of the hypothesis that in most, if not all, APS patients no major other signaling pathways are involved in aPL signaling. Furthermore, this in vitro observation may open up a novel therapeutic approach for APS patients, i.e. combined treatment with HCQ and rapamycin. HCQ is already widely used in the treatment of APS. Rapamycin is most commonly used as an immunosuppressant in organ transplantation, but other indications, e.g. autoimmune cytopenia and SLE, have been proposed [31, 32] . For SLE, there is some evidence of a beneficial effect of rapamycin [33] , but results of controlled clinical trials are lacking. The most striking evidence for a protective effect of rapamycin against aPL-induced effects derives from the work of Canaud et al., who showed that, after renal transplantation, transplant survival is compromised in a subgroup of patients with aPLs. This was not observed in the subgroup of aPL-positive patients receiving rapamycin immunosuppression [22] .
Finally, our data indicate that it may even be possible to tailor drug treatment according to aPL profile. Patients from group 1 might be treated with HCQ only, whereas patients from group 2 might be candidates for combined treatment with HCQ and rapamycin. Group 3 patients with only anti-b 2 GPI could be treated with rapamycin alone. However, this group is relatively small, so it might be difficult to obtain sufficient data. Although our in vitro data are promising, clinical studies will be needed to support this concept in the future.
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